Blog

  • TurnKey Renovation Company Introduces 15-Year Unlimited Wind Warranty for Roofing Projects

    TurnKey Renovation Company Introduces 15-Year Unlimited Wind Warranty for Roofing Projects

    November 13, 2025 – PRESSADVANTAGE –

    TurnKey Renovation Company has strengthened its reputation for customer-first service in the New Orleans area by announcing the addition of a 15-year Unlimited Wind Warranty. This extensive coverage provides a new level of security for property owners against the sometimes devastating effects of wind events, including those from named hurricanes and tropical storms that are frequent in southeastern Louisiana. By offering this warranty, TurnKey Renovation Company not only expands its commitment to quality craftsmanship but also provides much-needed peace of mind as storm season approaches each year.

    New Orleans homeowners and businesses know the unpredictable reality of wind and weather damage. Roofs must be constructed and maintained to withstand powerful gusts and severe climatic changes that can occur with little warning. TurnKey Renovation Company’s new 15-year Unlimited Wind Warranty rises to meet this challenge, giving clients a reliable safeguard for a remarkably long period—fifteen years from project completion. This warranty covers qualifying roof installations and renovations, offering reassurance that should wind damage occur, the company will respond promptly with repairs or solutions at no extra cost. Most importantly, this coverage includes significant windstorms, including hurricanes and named tropical events that frequently impact the region.

    Renovation company in New Orleans

    Behind this ambitious warranty is TurnKey Renovation Company’s team of experts, who apply a thorough and tailored approach to each project. Clients start with a detailed consultation and roof inspection to review structural factors, material selection, design considerations, and site-specific risks. The company’s experienced staff uses a blend of local knowledge and national best practices to engineer and construct roofs that are not only attractive but also exceptionally resilient. Each step of the renovation process is handled with a focus on detail and quality to ensure long-lasting, reliable results.

    The 15-year Unlimited Wind Warranty stands alongside TurnKey Renovation Company’s existing 10-year workmanship warranty, which further demonstrates a culture of accountability and trust. Homeowners and business owners alike benefit from a multi-tiered warranty approach that secures their investment for the long haul. Every client is provided with clear documentation about warranty rights, responsibilities, and what to expect should the unexpected occur. The company’s support team remains available for any future inquiries throughout the duration of the coverage.

    TurnKey Renovation Company also provides a full suite of home and commercial renovation services, including kitchen remodels, bathroom upgrades, deck and patio builds, custom storage and cabinetry, siding and exterior updates, painting, and more. Whether the aim is to improve curb appeal, modernize living spaces, or simply enhance property value, each project is delivered with personalized attention, transparent communication, and a dedication to exceeding client expectations. Numerous customer testimonials praise the company for prompt project delivery, outstanding craftsmanship, and especially for the confidence they feel knowing their investments are protected under strong warranty plans.

    With every project, TurnKey Renovation Company seeks to elevate both the quality of local buildings and the homeowner experience. The launch of the 15-year Unlimited Wind Warranty reaffirms the company’s proactive approach to challenges posed by the New Orleans climate. Those considering upgrades and seeking lasting protection are encouraged to contact TurnKey Renovation Company via their website to schedule a free consultation and learn how this new warranty can secure their property for the years ahead. TurnKey Renovation Company remains steadfast in its commitment to service, resilience, and the continued improvement of homes and businesses across the region.

    ###

    For more information about Turnkey Renovation Company, contact the company here:

    Turnkey Renovation Company
    Sharoon Wood
    504-209-7872
    info@turnkeyrenovationcompany.com
    New Orleans, LA

  • Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

    Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

    Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

    PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 14, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, announced today its financial and operating results for the quarter ending September 30, 2025, and highlighted important corporate updates.

    Third Quarter Corporate Highlights:

    • Skinject Clinical Development Program SKNJCT-003 & SKNJCT-004 Progress:

    The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States. SKNJCT-003, which commenced randomizing patients in August 2024, is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable doxorubicin-containing microneedle arrays (D-MNA).

    In August 2025, the Company announced that SKNJCT-003 has randomized more than seventy-five percent (75%) of the ninety (90) participants expected to be randomized in the study.

    In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of SkinJect, indicating that the Company may follow the FDA’s 505(b)(2) regulatory pathway to non-invasively treat BCC of the skin using dissolvable D-MNA.

    In October 2025, the Company treated its first patient in the clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi is the principal investigator.

    In November 2025, the company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.

    • Skinject Platform Expansion:

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, to explore co-development of thermostable infectious disease vaccines.

    • Pipeline Expansion-Acquisition of Antev

    In August 2025, the Company completed the acquisition of Antev Limited (“Antev”), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    • Patient Access & Advocacy-Gorlin Syndrome Alliance Collaboration

    In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable BCCs of the skin to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect in this rare disease population.

    Today the Company also announced its financial and operating results for the quarter ended September 30, 2025, highlights of which are provided below.

    Third Quarter Financial Highlights

    The addition of $10.4 million of aggregate net proceeds from financing transactions and the exercise of warrants has bolstered the Company’s already strong balance sheet as it continues to progress its clinical development program while pursuing strategic acquisition, building out its core management team and strengthening its board of directors.

    Cash and cash equivalents were $8.7 million at the end of the third quarter compared to $5.3 million at the end of the same period in 2024.

    • Total operating expenses were $15.4 million for the third quarter compared to $2.3 million for the same period in 2024.

    • Research and development expenses were $1.7 million for the third quarter compared to $0.6 million for the same period in 2024.

    • General and administrative expenses were $5.0 million for the third quarter compared to $1.8 million for the same period in 2024.

    • Net loss for the third quarter was $16.0 million compared to $2.3 million for the same period in 2024. This reflects increased expenses as the Company accelerates its clinical development program in United States, Europe and the Middle East, raises additional capital, completed the acquisition of Antev in the United Kingdom and continues to integrate Antev into its business and operations, as well as continues to pursue strategic growth.

    The Company’s complete financial statements for the quarter are included in its quarterly report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 14, 2025, and are also available on SEDAR+.

    Management Commentary

    “The fundamentals of the Company continue to remain strong,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman and CEO. “The clinical development program of SkinJect, which we believe represents more the $2 billion in potential market opportunity, is now active across the United States, Europe, and the Middle East. This expansion is enhancing global patient recruitment and our clinical dataset, which, among other things, is expected to assist us in designing a robust pivotal program. Completing the acquisition of Antev has been the highlight of the third quarter, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management levels. We believe, Teverelix, a next generation GnRH antagonist, is well positioned to become a first in class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6 billion in potential market opportunity. The Company’s balance sheet is stable, and management’s confidence level is high.”

    For further information contact:

    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicuspharma.com

    About Medicus Pharma Ltd.

    Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

    In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJectin this rare disease population.

    In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards

    Cautionary Notice on Forward-Looking Statements

    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • The UniqHouse Roswell Expands Kitchen Remodeling Services Across Metro Atlanta

    The UniqHouse Roswell Expands Kitchen Remodeling Services Across Metro Atlanta

    Roswell, Georgia – November 12, 2025 – PRESSADVANTAGE –

    The UniqHouse Roswell, a full-service home renovation company with over 15 years of experience, announces expanded remodeling services throughout the greater Atlanta metropolitan area, including Alpharetta, Johns Creek, Milton, Sandy Springs, Dunwoody, Woodstock, Marietta, Norcross, Cumming, and Mountain Park. The company specializes in comprehensive kitchen, bathroom, and basement transformations, offering integrated design and construction services from a single provider.

    The expansion comes as homeowners increasingly seek streamlined renovation solutions that eliminate the complexity of coordinating multiple contractors. The UniqHouse Roswell provides complete project management, from initial design consultation through final installation, utilizing in-house craftsmen and dedicated project managers for each renovation.

    Best Kitchen Remodeling Roswell Store

    “Homeowners deserve a renovation experience that transforms not just their spaces, but their entire approach to home improvement,” said a spokesperson for The UniqHouse Roswell. “Our integrated service model means clients work with one team throughout their project, whether they need Kitchen Remodeling Roswell Atlanta services or complete home transformations. This approach significantly reduces the stress and uncertainty that often accompanies major home renovations.”

    The company has earned recognition within the industry, receiving Best of Houzz awards in 2018, 2019, 2020, 2022, and 2023. These accolades reflect the company’s commitment to design excellence and customer satisfaction across all service categories.

    The UniqHouse Roswell offers free design consultations and 3D visualization services, allowing homeowners to preview their renovated spaces before construction begins. This technology-driven approach helps ensure that final results align with client expectations and design preferences. The company’s Cabinet Shop Roswell Atlanta provides custom cabinetry solutions tailored to each project’s specific requirements and aesthetic goals.

    The UniqHouse Roswell maintains partnerships with established kitchen and bath manufacturers throughout the United States, ensuring access to quality materials and innovative design solutions. All work includes a 12-month warranty from the original purchase date, providing additional assurance to homeowners investing in significant renovation projects.

    Beyond kitchen renovations, the company provides comprehensive Bathroom Remodeling Roswell Atlanta services, focusing on creating functional spaces that enhance daily routines. Basement finishing represents another core service area, with the company transforming underutilized spaces into valuable living areas that increase both home functionality and property value.

    The company employs licensed and insured professionals who handle all aspects of the renovation process, including permit acquisition, material selection, and installation. This comprehensive approach distinguishes The UniqHouse Roswell from contractors who may specialize in only one aspect of home renovation.

    The UniqHouse Roswell operates from its showroom location in Roswell, Georgia, where homeowners can view material samples, explore design options, and meet with design consultants. The company has built its reputation on delivering quality craftsmanship at competitive prices while maintaining transparent communication throughout each project phase. With expertise spanning kitchen remodeling, bathroom renovation, basement finishing, and complete home transformations, The UniqHouse Roswell continues to serve residential clients throughout the Atlanta metropolitan area.

    ###

    For more information about The UniqHouse Roswell, contact the company here:

    The UniqHouse Roswell
    The UniqHouse Roswell
    678-218-1993
    contact@theuniqhouse.com
    880 Holcomb Bridge Rd 110 B, Roswell, GA 30076, United States

  • Survivors of Abuse NJ Expands Resources for Survivors of Sexual Abuse and Assault

    Survivors of Abuse NJ Expands Resources for Survivors of Sexual Abuse and Assault

    MT. LAUREL, NJ – November 14, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced an expansion of its educational and informational resources to support survivors of sexual abuse and sexual assault throughout New Jersey. Based in Vineland, the organization continues its mission to increase awareness of civil legal rights, strengthen institutional accountability, and promote access to trauma-informed information for individuals impacted by abuse. The expansion reflects a growing statewide demand for accurate, accessible guidance regarding the legal and procedural aspects of pursuing justice.

    “Reliable information is critical for survivors who are considering their options within the civil justice system,” said Joseph L. Messa, Esq., attorney at Survivors of Abuse NJ. “Our goal is to make legal resources more accessible so individuals can better understand their rights and make informed decisions about how to move forward.”

    Vineland sexual abuse attorneys

    The newly expanded resources include written guides, informational workshops, and community outreach initiatives focused on civil remedies for survivors of sexual abuse and assault. These materials explain the steps involved in filing civil claims, outline available remedies, and describe how institutions can be held accountable when they fail to protect individuals from harm. Survivors of Abuse NJ developed the program in response to the ongoing need for clear, factual information about survivor rights, particularly in cases involving misconduct by professionals, educators, or organizational leaders.

    Civil litigation related to sexual abuse often extends beyond claims against individual perpetrators to include institutions responsible for oversight. Legal proceedings may involve schools, medical providers, religious organizations, or other entities that had a duty to prevent or report misconduct. Courts in New Jersey review whether these organizations fulfilled their obligations under state law, implemented proper supervision policies, and responded appropriately to allegations. In many instances, such cases lead to procedural reforms aimed at strengthening institutional safeguards and improving transparency.

    Legislative reforms in New Jersey have also played a major role in increasing access to justice for survivors. The New Jersey Child Victims Act, enacted in 2019, extended the time period for survivors to file civil claims for childhood sexual abuse. Under the law, individuals can now file claims until the age of fifty-five or within seven years of discovering the harm caused by the abuse. The act also opened a two-year window for previously time-barred cases, allowing many survivors to seek accountability for the first time. Survivors of Abuse NJ’s expanded resources include detailed explanations of this law and other provisions that affect the filing of civil claims.

    Educational outreach has become an integral part of the organization’s mission. Through its community partnerships, Survivors of Abuse NJ hosts public programs that provide factual guidance on legal procedures, trauma-informed advocacy, and institutional responsibility. These initiatives emphasize how survivors can navigate complex systems of reporting and litigation without being overwhelmed by legal terminology. By focusing on accessible, objective information, the organization helps bridge the gap between survivors and the resources available to them under state law.

    The organization’s approach to legal representation emphasizes trauma-informed practices. Attorneys collaborate with mental health professionals and support organizations to ensure survivors’ experiences are handled with sensitivity and respect. This approach prioritizes survivor autonomy, allowing individuals to retain control over decisions related to their cases. Clear communication and confidentiality are central to the model, which seeks to balance emotional considerations with procedural accuracy and legal compliance.

    Survivors of Abuse NJ’s expanded resources also include online informational materials accessible through the organization’s official platform. These materials outline how evidence is gathered, how claims progress through civil court, and what outcomes may be possible depending on the facts of each case. The organization’s goal is not to provide advice or representation through these materials but to ensure that survivors have a factual foundation upon which to base their next steps.

    Attorney Joseph L. Messa, Esq., and the firm’s team continue to work on initiatives that advance transparency and accountability within New Jersey’s institutions. As more survivors come forward under the expanded statutes, the organization remains focused on supporting them through accurate information, public education, and ethical legal advocacy. These combined efforts aim to improve institutional practices and strengthen legal systems designed to protect vulnerable individuals.

    Survivors of Abuse NJ continues to monitor developments in legislation and case law related to sexual abuse and assault. The organization regularly updates its materials to reflect the most current legal standards and reporting requirements. Through education, outreach, and advocacy, Survivors of Abuse NJ strives to foster greater understanding of survivors’ rights and to promote a culture of accountability within organizations across the state.

    For more information, visit the Survivors of Abuse NJ website.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054

  • RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

    RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

    ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.

    RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company’s market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.

    “Cidara’s journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors,” said Dave Gentry, CEO of RedChip Companies. “We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara’s vision and the importance of bringing promising small-cap opportunities to investors early.”

    As detailed in Merck’s announcement, the acquisition centers on CD388, Cidara’s investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.

    “Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip’s 33-year mission,” Gentry added. “We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow’s leading innovators today.”

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

    To learn more about RedChip’s products and services, please visit: https://www.redchip.com/corporate/investor_relations

    “Discovering Tomorrow’s Blue Chips Today”™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-REDCHIP (733-2447)
    1-407-644-4256
    info@redchip.com

    –END–

    SOURCE: RedChip Companies, Inc.

    View the original press release on ACCESS Newswire

  • Survivors of Abuse NJ Outlines Types of Sexual Abuse Cases Handled Across New Jersey

    Survivors of Abuse NJ Outlines Types of Sexual Abuse Cases Handled Across New Jersey

    MT. LAUREL, NJ – November 14, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced an overview of the types of sexual abuse cases the organization handles throughout New Jersey. Based in Atlantic City, the firm continues to expand public awareness about the scope of sexual abuse litigation and the civil remedies available to survivors under state law. The announcement underscores the organization’s mission to promote transparency, accountability, and access to justice for individuals affected by misconduct in institutional and professional settings.

    “Each sexual abuse case presents unique circumstances, and the civil justice system must address them with fairness and sensitivity,” said Joseph L. Messa, Esq., attorney at Survivors of Abuse NJ. “Our focus remains on helping survivors understand the different forms of abuse that can lead to civil action and the legal processes available to pursue accountability.”

    Atlantic City sexual abuse law firm

    Sexual abuse cases in New Jersey arise in a wide range of contexts involving both individual and institutional defendants. Survivors of Abuse NJ handles cases involving abuse by educators, medical professionals, religious leaders, coaches, and other individuals in positions of authority. These matters frequently include claims against institutions that employed or supervised the accused, based on alleged failures in oversight or reporting. The legal framework governing such cases is complex, requiring detailed evaluation of policies, professional standards, and the actions taken by organizations when allegations were first raised.

    One major category of civil litigation involves abuse in educational institutions. Cases may concern teachers, administrators, or staff who engaged in misconduct or failed to respond appropriately to reports of abuse. Courts review whether school districts met their obligations under state law to protect students, investigate complaints, and implement safeguarding procedures. When these duties are not fulfilled, institutions can face liability for negligence or inadequate supervision.

    Another significant category includes abuse by healthcare professionals. These cases often involve psychiatrists, physicians, therapists, or other licensed practitioners accused of exploiting their professional authority. Civil claims in this area examine whether professional boundaries were violated and whether facilities implemented adequate oversight. The sensitive nature of these cases requires both legal precision and trauma-informed care to ensure survivors’ experiences are treated with respect throughout the process.

    Religious institutions also represent a frequent setting for sexual abuse claims. Many of these cases involve misconduct by clergy members, employees, or volunteers, as well as allegations that organizations failed to investigate or report prior incidents. Civil litigation in this area focuses on institutional accountability and transparency, requiring a review of internal communications, training materials, and response protocols. The aim is not only to secure justice for survivors but also to encourage reforms that prevent future harm.

    Claims arising from sports, youth programs, and community organizations form another core area of Survivors of Abuse NJ’s practice. These cases often involve individuals in supervisory roles, such as coaches or group leaders, whose positions of authority allowed misconduct to occur. The legal process evaluates whether organizations followed background screening procedures, maintained adequate supervision, and enforced appropriate conduct standards. Institutions found to have neglected these duties may be held liable for damages under New Jersey civil law.

    Survivors of Abuse NJ’s work is guided by a trauma-informed approach that emphasizes clarity, confidentiality, and respect for survivors’ autonomy. The firm’s attorneys collaborate with mental health professionals, investigators, and experts to ensure that each case is evaluated comprehensively. By combining legal expertise with awareness of the psychological effects of trauma, the organization strives to make the legal process more accessible and supportive for those affected.

    Legislative developments in New Jersey have broadened the opportunities for survivors to seek justice. The New Jersey Child Victims Act extended the statute of limitations, allowing survivors to file claims until the age of fifty-five or within seven years of recognizing the harm caused by abuse. The act also opened a two-year window for older cases that were previously time-barred. These reforms have prompted renewed efforts to hold institutions accountable for past misconduct and have increased public awareness of survivors’ rights.

    In addition to litigation, Survivors of Abuse NJ engages in public education and outreach to inform communities about the civil legal process. The organization’s materials and seminars explain how claims are filed, what evidence is required, and how institutions can implement stronger preventive measures. These initiatives are designed to ensure that survivors and community members understand the broader social and legal implications of sexual abuse and the steps available to promote systemic change.

    Attorney Joseph L. Messa, Esq., continues to play an active role in advancing survivor advocacy within the civil justice system. His experience in personal injury and institutional misconduct cases informs the firm’s commitment to fairness and integrity in all proceedings. Through continued education, legal representation, and outreach, Survivors of Abuse NJ contributes to statewide efforts to strengthen protections for survivors and to improve accountability within organizations entrusted with care and supervision.

    For more information, visit the Survivors of Abuse NJ website. To learn more about survivor education and legal initiatives, contact Survivors of Abuse NJ directly.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054

  • DataField Implements Enhanced Candidate Screening Process to Support Columbus IT Growth

    DataField Implements Enhanced Candidate Screening Process to Support Columbus IT Growth

    November 12, 2025 – PRESSADVANTAGE –

    DataField Technology Services announced the implementation of an enhanced candidate screening process designed to ensure greater precision, reliability, and retention in DataField’s IT staffing placements across Columbus. This refined procedure represents a significant step toward addressing one of the most pressing challenges in the technology sector—aligning skilled professionals with organizations seeking dependable, long-term talent.

    As the regional demand for IT expertise continues to grow, businesses in Columbus are facing increasing pressure to secure professionals with not only the right technical capabilities but also the adaptability and workplace compatibility needed to succeed in complex environments. DataField’s new multi-phase screening process was developed in response to this demand, refining every step of candidate evaluation to improve both the quality and longevity of placements.

    DataField Technology Services IT staffing department works together to match employees with companies.

    According to the company, the enhanced process is built upon a combination of data validation, structured interviews, technical verification, and behavioral analysis, forming a comprehensive vetting framework that minimizes mismatched hires. By focusing on measurable competency and cultural alignment, DataField aims to provide its clients with professionals who not only meet technical requirements but also contribute to organizational stability and growth.

    “The new screening structure was developed after evaluating placement outcomes over several years,” said Courtland Bishop, President and CEO of DataField Technology Services in Columbus, Ohio. “We found that improving early-stage assessments—particularly in technical verification and behavioral screening—produced measurable gains in candidate retention and employer satisfaction,” Bishop added that the company’s analysis revealed significant reductions in turnover rates when enhanced assessment tools were applied during initial candidate evaluation.

    Each stage of the updated process is designed to ensure objective decision-making supported by evidence and metrics rather than assumptions. Candidates undergo multiple rounds of technical assessments aligned with the latest standards in software development, cybersecurity, and network management. These assessments are complemented by scenario-based interviews, during which recruiters evaluate communication skills, problem-solving approaches, and adaptability in collaborative settings. This multifaceted approach not only ensures technical proficiency but also identifies individuals most likely to succeed in fast-paced or specialized environments.

    A crucial aspect of the framework involves advanced background verification and reference validation. Beyond standard checks, DataField’s procedure now incorporates deeper employment record analysis and verification of project-specific contributions. The purpose is to authenticate experience at a granular level, ensuring that claimed expertise corresponds to actual professional performance. According to Bishop, this detailed verification process is essential to maintaining trust with clients who rely on DataField’s recommendations for critical IT roles.

    The refinement of the onboarding process also emphasizes data-driven decision-making. By leveraging insights gathered from placement outcomes, client feedback, and retention data, DataField continuously calibrates its selection parameters. Bishop explained that ongoing monitoring enables the company to make evidence-based improvements, ensuring that both clients and candidates experience measurable benefits over time. “Data doesn’t lie,” Bishop noted. “When you study the lifecycle of a placement—how long it lasts, the productivity outcomes, and client feedback—you see where screening improvements truly make an impact.”

    The company reports that the enhanced candidate screening has already produced early indicators of improved placement success. Preliminary internal data suggests that positions filled through the new process demonstrate longer retention periods and higher post-placement satisfaction ratings from both clients and candidates. DataField attributes these results to a more deliberate matching system that factors in both technical fit and organizational culture.

    For Columbus employers, these operational changes arrive at a critical moment. The local technology sector continues to expand rapidly, with new businesses emerging and established companies increasing their digital infrastructure needs. However, with that growth comes a competitive labor market, where the cost of a mismatched hire can have significant financial and operational repercussions. DataField’s improved IT staffing process is positioned to mitigate those risks by ensuring that placements are not only qualified but sustainable.

    Bishop emphasized that while automation and data analytics play a role in modern staffing, human oversight remains central to DataField’s model. “Our recruiters bring professional judgment to every evaluation,” Bishop said. “Technology helps us process data efficiently, but the experience of our team—knowing how to interpret that data in real-world contexts—is what delivers lasting results.” His remarks underscore the company’s belief that the combination of analytical precision and human expertise provides the most reliable framework for workforce alignment.

    The company’s IT staffing enhancements also reflect a broader commitment to transparency and accountability in staffing. By standardizing its internal review protocols and maintaining consistent reporting metrics, DataField seeks to establish a higher benchmark for reliability within the IT recruitment industry. The process is not simply about screening candidates; it is about creating a repeatable, verifiable system of quality assurance that benefits both employers and professionals seeking stable placements.

    Bishop stated that the goal is to create a model that can adapt as the technology landscape evolves. With the rapid adoption of artificial intelligence, cloud computing, and cybersecurity advancements, the company anticipates that hiring requirements will continue to diversify. “What makes a successful placement today may not be what defines success in five years,” Bishop observed. “That’s why our process must be dynamic—responsive to market changes while maintaining the integrity of our screening standards.”

    The company expects its refined process to set a new operational standard for IT staffing in the Columbus market. By grounding its methods in measurable outcomes and focusing on long-term compatibility, DataField aims to build greater confidence among businesses seeking to strengthen their technical teams. Employers benefit not only from reduced hiring risks but also from the assurance that candidates recommended by DataField have undergone rigorous evaluation.

    The implementation of this improved system reinforces DataField’s broader mission of connecting organizations with technology professionals capable of sustaining innovation, reliability, and growth. For businesses in Columbus seeking dependable IT staffing solutions, more information about DataField’s specialized services can be found at https://datafieldusa.com/it-staffing/

    ###

    For more information about DataField Technology Services, contact the company here:

    DataField Technology Services
    Telecom engineers
    16148479600
    Sales@datafieldusa.com

  • The UniqHouse Norcross Announces Expanded Bathroom Remodeling Services Across Atlanta Metropolitan Area

    The UniqHouse Norcross Announces Expanded Bathroom Remodeling Services Across Atlanta Metropolitan Area

    Norcross, Georgia – November 12, 2025 – PRESSADVANTAGE –

    The UniqHouse Norcross, an award-winning home remodeling company with over 15 years of experience, announces the expansion of its comprehensive remodeling services throughout the Atlanta metropolitan area, including specialized bathroom and kitchen renovation solutions for homeowners in Alpharetta, Johns Creek, Milton, Sandy Springs, and surrounding communities.

    The company, which operates showrooms in both Norcross and Roswell, has established itself as a full-service remodeling contractor offering kitchen renovations, bathroom transformations, and basement finishing services. The expansion reflects growing demand for professional home renovation services in the greater Atlanta region, where homeowners increasingly seek experienced contractors who can manage complete projects from design through installation.

    Bathroom Remodeling Norcross

    “The Atlanta market continues to show strong interest in home improvement projects, particularly in Bathroom Remodeling Norcross Atlanta areas where property values benefit from quality renovations,” said a spokesperson for The UniqHouse Norcross. “Our approach combines detailed planning with expert craftsmanship to deliver transformations that enhance both functionality and aesthetic appeal while maintaining reasonable pricing for homeowners.”

    The company’s service expansion addresses the needs of homeowners seeking comprehensive renovation solutions without the complexity of coordinating multiple contractors. Each project includes professional design consultation, material selection assistance, permit management, and installation services. The UniqHouse maintains partnerships with established kitchen and bath manufacturers across the United States, providing clients access to quality materials and contemporary design options.

    Recent industry data indicates that bathroom and kitchen renovations remain among the most valuable home improvements for property owners. The National Association of Realtors reports that these renovations typically recover 60 to 80 percent of their cost at resale, making them practical investments for homeowners planning to remain in their properties or prepare for future sales.

    The UniqHouse’s renovation process begins with complimentary design consultations where homeowners discuss their vision and requirements with experienced designers. The company utilizes 3D design technology to help clients visualize proposed changes before construction begins. Services include complete kitchen remodeling projects, Bathroom Vanity Norcross Atlanta installations, and basement finishing solutions tailored to individual household needs.

    The company has received multiple industry recognitions, including Best of Houzz awards in 2023, 2022, 2020, 2019, and 2018. These acknowledgments reflect the company’s commitment to design excellence and customer satisfaction across its service areas, which now include Alpharetta, Johns Creek, Milton, Sandy Springs, Dunwoody, Woodstock, Marietta, Norcross, Cumming, Mountain Park, and Roswell.

    Each remodeling project is managed by dedicated project managers who coordinate all aspects of the renovation, from initial measurements through final installation. The company employs in-house craftsmen rather than subcontractors, maintaining quality control throughout the renovation process. All work includes a 12-month warranty from the original date of purchase.

    The UniqHouse Norcross specializes in luxury remodeling services that transform residential spaces into functional environments tailored to homeowner preferences. The company’s portfolio encompasses kitchen remodeling Atlanta, bathroom remodeling, basement remodeling, and complete home renovations, with showroom locations available for clients to view materials and design options.

    ###

    For more information about The UniqHouse Norcross, contact the company here:

    The UniqHouse Norcross
    The UniqHouse Norcross
    470-828-2939
    contact@theuniqhouse.com
    6695 A Jimmy Carter Boulevard Norcross, GA

  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States

    Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States

    NEW YORK, Nov. 14, 2025 / PRZen / Outreaching.io announced today that Rameez Ghayas Usmani has been appointed as the company’s Chief Executive Officer. According to the board of directors, the appointment reflects Rameez’s professional experience in digital PR and SEO, as well as his recognition as the Best HARO Link Building Expert in the United States by BestofBestReview.com

    Rameez has extensive experience with HARO (Help A Reporter Out) and Qwoted outreach, connecting organizations with journalists to secure editorial backlinks from reputable publications. His work includes structured campaigns across multiple sectors aimed at delivering consistent, measurable media placements and strengthening professional outreach practices.

    In his new role, Rameez will oversee strategic operations at Outreaching.io and guide initiatives in digital PR and SEO. The board emphasized that the appointment aligns with the company’s plans to reinforce executive leadership and operational continuity as it continues to grow.

    Rameez has worked with clients across technology, finance, healthcare, and e-commerce, focusing on editorially earned placements. The board stated that his experience supports Outreaching.io’s commitment to ethical outreach and professional standards in link-building strategies.

    “This appointment reflects the board’s confidence in Rameez’s professional expertise,” said a spokesperson for Outreaching.io. “His recognition as the Best HARO Link Building Expert in the United States highlights his understanding of industry practices and the company’s dedication to structured, ethical media outreach.”

    As CEO, Rameez will implement systems to support consistent outreach practices, including tools for media opportunity tracking and reporting. These initiatives are intended to maintain professional standards in HARO link building and support reliable service delivery to clients.

    The board noted that Rameez will also contribute to policy development and staff guidance, ensuring high-quality outreach services across all client accounts. His leadership is expected to reinforce Outreaching.io’s focus on ethical, results-oriented digital PR and link-building practices.

    Under Rameez’s direction, Outreaching.io is targeting faster turnaround times for client campaigns, higher placement rates in Tier-1 publications, and measurable growth in clients’ inbound leads from earned media including New York Times, Forbes, Business Insider, and more. Recognized as the Best HARO Link Building Expert, Rameez is implementing systems to optimize the company’s HARO pipeline—shortening response cycles and improving journalist-brand match accuracy.

    The board stated that these operational goals are intended to strengthen client ROI and reinforce Outreaching.io’s position as a leader in credible, performance-driven HARO link building.

    About Outreaching.io

    Outreaching.io is a link-building and digital PR agency. The agency provides journalist outreach and HARO link-building services to clients across multiple industries. Its approach emphasizes authentic relationships with media professionals and measurable results in organic visibility and authority.

    Media Contact
    Outreaching.io – Rameez Ghayas Usmani
    +971585709698
    rameez@outreaching.io

    Press Release Distributed by PRLog

    Source: Outreaching.io

    Follow the full story here: https://przen.com/pr/33598505

  • 5E Advanced Materials Hosts Q1 Call; Highlights Federal Recognition of Boron, Customer Validation, and Progress Toward 2026 FID

    5E Advanced Materials Hosts Q1 Call; Highlights Federal Recognition of Boron, Customer Validation, and Progress Toward 2026 FID

    HESPERIA, CA / ACCESS Newswire / November 14, 2025 / 5E Advanced Materials, Inc. (“5E” or the “Company”) (Nasdaq:FEAM)(ASX:5EA), a development stage company focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron derivative materials, today announced key takeaways from its fiscal first-quarter conference call.

    Chief Executive Officer Paul Weibel outlined momentum across policy, customers, engineering, and financing that supports 5E’s path to a Final Investment Decision (FID) in 2026.

    Highlights from the call included:

    • Boron designated a U.S. Critical Mineral (Nov 7, 2025) – The U.S. Geological Survey and Department of the Interior formally added boron to the Final 2025 Critical Minerals List, validating boron’s role in U.S. energy, defense, and advanced manufacturing supply chains strengthening Fort Cady’s strategic position.

    • Expanded access to U.S. federal programs – With the critical-mineral designation, 5E believes Fort Cady is eligible for multiple federal funding and financing channels, including EXIM Bank (building on a previously received US$285M Letter of Interest under “Make More in America”) and an EXIM Engineering Multiplier application for US$10M to support FEED; additional pools of capital discussed include DOE’s LPO, the Office of Strategic Capital, and the U.S. International Development Finance Corporation.

    • Customer validation advancing – Full-scale product testing is underway with Tier-1 specialty glass manufacturers. A 20-ton shipment of high-purity boric acid arrived in Taiwan for furnace trials; additional LCD-glass producers are queued for shipments. 5E also supplied 1,000 lbs. of boric acid to a U.S. boron-carbide manufacturer supporting domestic re-shoring.

    • Resource Statement Upgrade – The Company has secured and recorded the remaining federal lode claims for the colemanite deposit. A workstream has commenced to upgrade its mineral resource statement.

    • Intellectual Property Portfolio – The Company expects to file a portfolio of preliminary patents to secure intellectual property for its proprietary mining techniques and processing solutions.

    • Engineering and economics – The Company is nearing completion of FEED-ready deliverables. Previously disclosed economics for Phase 1 of Fort Cady continue to anchor planning (approximately 39.5-year mine life, ~16% after-tax IRR, and ~US$469M after-tax NPV), supporting a disciplined, de-risked approach toward construction readiness.

    • Track to 2026 FID – Priorities include (1) securing non-dilutive U.S. capital support, (2) converting customer progress into commercial offtake agreements, and (3) executing FEED and pre-FID workstreams to ensure construction readiness.

    “This quarter represents an inflection point with federal recognition, growing customer traction, and steady execution, placing 5E on a clear path to become America’s trusted domestic supplier of advanced boron materials,” said Paul Weibel, Chief Executive Officer. “We are progressing methodically, de-risking each stage, and aligning our capital structure to support long-term value creation.”

    A replay of the First Quarter Fiscal Year 2026 shareholder call is now available HERE.

    About 5E Advanced Materials, Inc.

    5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron materials, complemented by calcium-based co-products, and potentially other by-products such as lithium carbonate. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, energy independence, food, national security, and the defense sector. The Company believes factors such as government regulation and incentives focused on domestic manufacturing and supply chains and capital investments across industries will drive demand for end-use applications like solar and wind energy infrastructure, neodymium-ferro-boron magnets, defense applications, lithium-ion batteries, and other critical material applications. The business is based on the Company’s large domestic boron resource, a mineral which was added to the U.S. Department of the Interior’s 2025 Critical Minerals List. The project is located in Southern California and designated as Critical Infrastructure by the U.S. Department of Homeland Security.

    Forward Looking Statements

    Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the Company’s ability to progress, full-scale product testing, advance customer qualifications, enter into offtake agreements, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. Any forward-looking statements are based on 5E’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the Company’s ability to progress to full-scale product testing, enter into long-term supply agreements, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled ‘Risk Factors’ in 5E’s most recent Annual Report on Form 10-K and its other reports filed with the SEC. Forward-looking statements contained in this announcement are based on information available to 5E as of the date hereof and are made only as of the date of this release. 5E undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing 5E’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of 5E.

    For further information contact:

    Michael MacMillan or Paola Ashton
    PRA Communications
    team@pracommunications.com
    Ph: +1 (604) 681-1407

    SOURCE: 5E Advanced Materials, Inc.

    View the original press release on ACCESS Newswire